References: 1. CYCLOSET [prescribing information]. Tiverton, RI: VeroScience, LLC. 2. DeFronzo
RA. Bromocriptine: a sympatholytic, D2-dopamine agonist for the treatment of type 2 diabetes. Diabetes Care.
2011;34(4):789-794. 3. American Diabetes Association. Postprandial Blood Glucose. Diabetes Care.
2001:24(4):775-778. 4. Sclaich M, Strazinsky N, Lambert E, et al. Metabolic syndrome: a sympathetic disease?
Lancet Diabetes Endocrinol. 2015:3(2):148-157.
5. Rogowski O, Steinvil A, Berliner S, et al. Elevated resting heart rate is associated with the metabolic
syndrome. Cardiovasc Diabetol. 2009;8:55. doi: 10.1186/1475-2840-8-55. 6. Chamarthi B, Vinik AI, Ezrokhi M, et
al. Dopamine agonist therapy reduces elevated heart rate and dysglycemia in type 2 diabetes subjects. Diabetes.
2016;65(Suppl1):A317. 7. Geerling JJ, Boon MR, Kooijman S, et al. Sympathetic nervous system control of
triglyceride metabolism: novel concepts derived from recent studies. J Lipid Res. 2014;55(2):180-189. 8.
Cincotta AH, Ezrokhi M. The anti-diabetes efficacy of Bromocriptine-QR in type 2 diabetes mellitus (T2DM)
subjects is enhanced among those with elevated blood pressure and plasma triglyceride levels. Diabetes. 2013;
62(suppl 1):A305. 9. Tentolouris N, Argyrakopoulou G, Katsilambros N. Perturbed autonomic nervous system
function in metabolic syndrome. Neuromolecular Med. 2008;10(3):169-178. 10. Thorp AA, Sclaich MP. Relevance of
sympathetic nervous system activation in obesity and metabolic syndrome. J. Diabetes Res. 2015;2015:341583. 11.
Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered
approach: position statement of the American Diabetes Association (ADA) and the European Association for the
Study of Diabetes (EASD). Diabetes Care. 2012;35(6):1364-1379.